Skip to main content

Table 1 Clinicopathological characteristics of AML patients from TCGA cohort

From: Pan-cancer analysis of oncogenic TNFAIP2 identifying its prognostic value and immunological function in acute myeloid leukemia

Characteristic

Low expression of TNFAIP2 (n = 75)

High expression of TNFAIP2 (n = 76)

P value

Gender (male), n (%)

41 (27.2%)

42 (27.8%)

1.000

Age, median (IQR)

51 (35.5, 61.5)

62 (48, 70.25)

< 0.001

WBC count(× 109/L), median (IQR)

13 (3, 39.5)

27 (6.75, 69)

0.018

Cytogenetic risk, n (%)

 Favorable

21 (14.1%)

10 (6.7%)

0.024

 Intermediate

38 (25.5%)

44 (29.5%)

0.369

 Poor

15 (10.1%)

21 (14.1%)

0.27

FAB classifications, n (%)

 M0

9 (6%)

6 (4%)

0.384

 M1

16 (10.7%)

19 (12.7%)

0.625

 M2

26 (17.3%)

12 (8%)

0.006

 M3

14 (9.3%)

1 (0.7%)

0.001

 M4

4 (2.7%)

25 (16.7%)

< 0.001

 M5

3 (2%)

12 (8%)

0.034

 M6

1 (0.7%)

1 (0.7%)

1.000

 M7

1 (0.7%)

0 (0%)

0.493

Cytogenetics, n (%)

 Normal

35 (25.9%)

34 (25.2%)

0.718

  + 8

3 (2.2%)

5 (3.7%)

0.620

 del(5)

1 (0.7%)

0 (0%)

1.000

 del(7)

1 (0.7%)

5 (3.7%)

0.172

 inv.(16)

1 (0.7%)

7 (5.2%)

0.051

 t(15;17)

11 (8.1%)

0 (0%)

0.001

 t(8;21)

7 (5.2%)

0 (0%)

0.014

 t(9;11)

0 (0%)

1 (0.7%)

0.478

 Complex

12 (8.9%)

12 (8.9%)

0.809

OS event, n (%)

  

0.023

 Alive

34 (22.5%)

20 (13.2%)

 

 Dead

41 (27.2%)

56 (37.1%)

 
  1. n number of patients, IQR Interquartile range, WBC White blood cell, FAB French–American–British subtype